Effects of Febuxostat on Adipokines and Kidney Disease in Diabetic Chronic Kidney Disease
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Diabetes |
| Therapuetic Areas: | Endocrinology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/1/2014 |
| Start Date: | May 2011 |
| End Date: | December 2013 |
| Contact: | Srinivasan Beddhu, MD |
| Email: | srinivasan.beddhu@hsc.utah.edu |
| Phone: | 801-581-3810 |
Hyperuricemia is emerging as a risk factor for development of diabetes and metabolic
syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia
induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of
uric acid with febuxostat we hypothesize that the levels of oxidative stress in adipose
tissue (obtained by fat biopsy) will decrease.
Primary aims of the study is to determine whether febuxostat therapy in overweight or obese,
diabetic patients with stage 3 CKD and high serum uric acid levels
1. decreases adipose tissue concentrations of thiobarbituric acid reactive substance
(TBARS), a marker of oxidative stress
2. increases adipose tissue expression and concentrations of adiponectin and
3. decreases urinary concentrations of transforming growth factor (TGF)- B1.
syndrome. Recently, it was shown in in-vitro cell culture experiments that hyperuricemia
induces redox-dependent signaling and oxidative stress in adipocytes. By targeting levels of
uric acid with febuxostat we hypothesize that the levels of oxidative stress in adipose
tissue (obtained by fat biopsy) will decrease.
Primary aims of the study is to determine whether febuxostat therapy in overweight or obese,
diabetic patients with stage 3 CKD and high serum uric acid levels
1. decreases adipose tissue concentrations of thiobarbituric acid reactive substance
(TBARS), a marker of oxidative stress
2. increases adipose tissue expression and concentrations of adiponectin and
3. decreases urinary concentrations of transforming growth factor (TGF)- B1.
Inclusion Criteria:
- Age > 18 years
- BMI > 25 kg/m2
- type 2 diabetes
- serum uric acid ≥ 5.5 mg/dl in men and ≥ 4.6 mg/dl in women
- eGFR 30-60 mL/min/1.73m2
Exclusion Criteria:
- History of gout
- concurrent use of azathioprine, mercaptopurine, theophylline, allopurinol,
thiazolidinediones or warfarin
- concurrent use of metformin
- current antibiotic therapy
- pregnant women
- prisoners
We found this trial at
1
site
University of Utah Research is a major component in the life of the U benefiting...
Click here to add this to my saved trials
